USING KETAMINE IN
Ketamine is a fascinating medicine with rapid-acting antidepressant effects and visionary properties. The goal of this class is to help psychoanalytically oriented psychotherapists identify which patients might benefit from a referral for adjunctive ketamine treatment, and to evaluate whether they might want to work with ketamine lozenges in their clinical practices, which is possible using a triadic treatment model (patient, psychotherapist, prescriber). In the first half of this talk, the presenters will explain several different paradigms for thinking about ketamine treatment: a pharmaceutical and biochemical approach, a psychotherapeutic and relational approach, and a psychedelic and shamanic approach. Then the presenters will talk about which patients are good candidates for ketamine treatment, and which patients would not be a good fit. Next, a discussion on the legal and logistical issues in adding ketamine services. In the second half of this workshop, the presenters will talk about the natural intersection between working with ketamine and psychoanalytic treatment. Case material will be presented.
NCSPP is aware that historically psychoanalysis has either excluded or pathologized groups outside of the dominant population in terms of age, race, ethnicity, nationality, language, gender, religion, sexual orientation, socioeconomic status, disability, and size. As an organization, we are committed to bringing awareness to matters of anti-oppression, inequity, inequality, diversity, and inclusion as they pertain to our educational offerings, our theoretical orientation, our community, and the broader world we all inhabit.
One of the objectives of this course is to help clinicians provide more effective and economical care to all of their patients, including patients who identify as a member of an under-seen or under-served group. For example, we have experience in working with LGBT youth and individuals, who have an increased risk for depression, anxiety, or suicide attempts related to difficulties in their families of origin or past bullying. We have experience in working with older adults who are experiencing depression related to health concerns or social isolation. We have experience in working with people who are living with disabilities, chronic pain, and depression. We strive to provide efficacious, culturally Informed, non-judgmental, and cost effective mental health services.
At the conclusion of this course, participants will be able to:
- Describe 3 paradigms for ketamine treatment: medical, psychological, psychedelic.
- Name the current clinical indications for ketamine treatment, according to the most current medical literature.
- Describe and discuss the overlapping principals of ketamine and psychoanalytic treatment.
- Acevedo-Diaz, E.E., Cavanaugh, G.W., Greenstein, D., Kraus, C., Kadriu, B., Zarate, C.A. Jr, & Park, L.T. (2019). Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. Journal of Affective Disorders.
- Dakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M.,... & Levin, F. R. (2019). A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: A randomized clinical trial. American Journal of Psychiatry, 176(11), 923-930. doi: 10.1016/j.neuropharm.2018.01.005
- Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019). Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy, Journal of Psychoactive Drugs, 51(2), 189-198. doi: 10.1080/02791072.2019.1587556
- Gardner, C. (2017). Case report reveals successful treatment of adolescent depression with ketamine. Yale School of Medicine. Retrieved from: https://medicine.yale.edu/news-article/14682/
- George, D., Gálvez, V., Martin, D., Kumar, D., Leyden, J., Hadzi-Pavlovic, D.,...& Loo, C. (2017). Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression. The American Journal of Geriatric Psychiatry, 25(7), 1199-1209. doi: 10.1016/j.jagp.2017.06.007
- Katzman, J. (2018). Rapid depression remission and the "therapeutic bends" with ketamine-assisted psychotherapy. Psychedelics Today. Retrieved from: https://www.healingrealmscenter.com/blog/rapid-depression-remission-and-the-therapeutic-bends
- Mathai, D. S., Meyer, M. J., Storch, E. A., & Kosten, T. R. (2020). The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. Journal of Affective Disorders, 264, 123-129.
- Ryan, W. C., Marta, C. J., & Koek, R. J. (2014). Ketamine and depression: A review. International Journal of Transpersonal Studies, 33(2), 40–74. doi: 10.24972/ijts.2014.33.2.40
- Ross, C., Jain, R., Bonnett, C. J., & Wolfson, P. (2019). High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans. Annals of Clinical Psychiatry, 31(4), 271-279.
- Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., & Nemeroff, C. B. (2017). A Consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry, 74(4), 399-405. doi:10.1001/jamapsychiatry.2017.0080
- Turban, J. (2017). The ketamine breakthrough for suicidal children. Scientific American. Retrieved from: https://www.scientificamerican.com/article/the-ketamine-breakthrough-for-suicidal-children/
- Zarrinnegar, P., Kothari, J., & Cheng, K. (2019). Successful use of ketamine for the treatment of psychotic depression in a teenager. Journal of Child and Adolescent Psychopharmacology, 29(6), 472-473. doi: 10.1089/cap.2019.0028
Raquel Bennett, Psy.D., is a psychologist and ketamine specialist in Berkeley. She primarily works with people who are living with severe depression, bipolar disorder, and/or suicidal ideation. Founder of KRIYA Institute, focused on ketamine research, Dr. Bennett has a long-standing interest in the psychedelic and mystical properties of ketamine.
Megan Rundel, Ph.D., is a personal and supervising analyst and on the faculty of PINC. A graduate of the Center for Psychedelic Therapy and Research at CIIS, Dr. Rundel’s Oakland-based psychoanalytic practice combines her interest in depth psychology, spirituality, and psychedelic integration.
This is an introductory level course that would be appropriate for any medical or mental health professional.
LCSW/MFTs: Course meets the requirements for _ hours of continuing education credit for LMFTs, LCSWs, LPCCs and/or LEPS, as required by the CA Board of Behavioral Sciences. NCSPP is approved by the California Association of Marriage and Family Therapists (Provider Number 57020), to sponsor continuing education for LMFTs, LCSWs, LPCCS, and/or LEPs. NCSPP maintains responsibility for this program /course and its content.
Psychologists: Division 39 is approved by the American Psychological Association to sponsor continuing education for psychologists. Division 39 maintains responsibility for these programs and their content.
Enrollees who cancel at least SEVEN DAYS prior to the event date will receive a refund minus a $35 administrative charge. No refunds will be allowed after this time. Transfer of registrations are not allowed.